Navigation Links
Omnicell Announces Fourth Quarter and Full-Year 2009 Results

MOUNTAIN VIEW, Calif., Jan. 28 /PRNewswire-FirstCall/ -- Omnicell, Inc. (Nasdaq: OMCL), a leading provider of system solutions to acute healthcare facilities, today announced results for its fourth quarter and year ended December 31, 2009.

GAAP results: Revenue for the fourth quarter of 2009 was $54.7 million, up $0.7 million or 1.3% from the third quarter of 2009, and down $7.4 million or 11.9% from the fourth quarter of 2008.  Revenue for the year ended December 31, 2009 was $213.5 million, down $38.4 million or 15.2% from the year ended December 31, 2008.

Fourth quarter 2009 net income as reported in accordance with U.S. generally accepted accounting principles (GAAP) was $0.6 million, or $0.02 per diluted share. This compares to net income of $0.9 million, or $0.03 per diluted share in the third quarter of 2009 and net income of $3.3 million, or $0.10 per diluted share in the fourth quarter of 2008. For the year ended December 31, 2009, net income was $0.4 million, or $0.01 per diluted share. This compares to net income of $12.7 million, or $0.38 per diluted share for the year ended December 31, 2008.

Non-GAAP results: Excluding the impact on our results of recording $2.5 million in stock-based compensation expense related to ASC 718, "Stock Compensation" (formerly referred to as SFAS No. 123R) and $0.4 million in income tax expense related to prior year research and development tax credits, non-GAAP net income was $3.4 million for the fourth quarter of 2009, or $0.11 per diluted share. This compares to non-GAAP net income of $3.3 million, or $0.10 per diluted share for the third quarter of 2009, which excluded $2.4 million in stock-based compensation expense, and non-GAAP net income of $5.5 million, or $0.17 per diluted share for the fourth quarter of 2008, which excluded $2.4 million of stock-based compensation expense and $0.2 million of income tax benefits related to prior year research and development tax credits.  Excluding $9.7 million in stock-based compensation expense, $2.5 million non-recurring costs ($1.5 million, net of tax) from our first quarter of 2009 restructuring activities and $0.4 million in income tax expense related to prior years research and development tax credits, non-GAAP net income was $12.1 million for the year ended December 31, 2009, or $0.38 per diluted share.  Excluding $11.2 million in stock-based compensation expense and $0.2 million in income tax benefits related to prior years research and development tax credits, non-GAAP net income was $23.6 million for the year ended December 31, 2008, or $0.71 per diluted share.

Product backlog as of December 31, 2009 totaled $114 million, up $4 million or 4% from December 31, 2008.

"The 2009 fourth quarter saw Omnicell secure first orders from some of the most prestigious hospital networks in the United States including Carolinas Health System, CoxHealth and NewYork-Presbyterian," said Randall Lipps, president and CEO of Omnicell. "We remain confident that customers are recognizing our solution's unique benefits and are committed to improving the efficiencies and safety in their facilities. It has been a rewarding quarter, and we expect continued growth in 2010."

Omnicell Conference Call Information

Omnicell will hold a conference call today at 1:30 p.m. PST to discuss fourth quarter and 2009 year-end financial results. The conference call can be monitored by dialing 1-800-696-5518 within the U.S. or 1-706-758-4883 for all other locations. The Conference ID # is 52186247. Internet users can access the conference call at A replay of the call will be available today at approximately 2:30 p.m. PST and will be available until 8:59 p.m. PST on February 26. The replay access numbers are 1-800-642-1687 within the U.S. and 1-706-645-9291 for all other locations, conference code # 52186247.

About Omnicell

Omnicell, Inc. (NASDAQ: OMCL) is a leading provider of systems that enable healthcare facilities to increase operational efficiency, enhance patient safety and allow clinicians to spend more time with their patients.

Founded in 1992, Omnicell's medication-use solutions include complete automation systems for the central pharmacy, anesthesia workstations for the operating room, dispensing cabinet systems for nursing units, and safe, secure medication transportation and verification systems to the patient bedside. From a medication's arrival at the receiving dock to its dosing to the patient, Omnicell systems store it, package it, bar code it, order it, issue it, and provide information and controls on its use and reorder.

Omnicell supply product lines provide a healthcare institution with comprehensive supply chain solutions that result in fast, effective control of costs, capture of charges for payer reimbursement, and timely reorder of supplies. Products range from high-security closed-cabinet systems and software to open-shelf and combination solutions in the nursing unit, cath lab and operating room.

For more information, visit

Forward-Looking Statements

To the extent any statements contained in this release deal with information that is not historical, these statements are necessarily forward-looking. As such, they are subject to the occurrence of many events outside Omnicell's control and are subject to various risk factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. The risk factors are described in the Company's Securities and Exchange Commission (SEC) filings and include, without limitation, the unfavorable general economic and market conditions and decreased demand for capital equipment, the lack of available credit opportunities, the continued growth and acceptance of our products and services and the continued growth of the clinical automation and workflow automation market generally, the potential of increasing competition, the ability of the company to grow product backlog, retain key personnel, cut expenses, manage future changes in revenue levels, develop new products and integrate acquired products or intellectual property in a timely and cost-effective manner, and improve sales productivity. Prospective investors are cautioned not to place undue reliance on forward-looking statements.

Use of Non-GAAP Financial Information

This press release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). Our management evaluates and makes operating decisions using various performance measures. In addition to Omnicell's GAAP results, we also consider non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share.  These non-GAAP results should not be considered as an alternative to gross profit, operating expenses, net income, earnings per diluted share, or any other performance measure derived in accordance with GAAP.  We present these non-GAAP results because we consider them to be important supplemental measures of Omnicell's performance.

Our non-GAAP gross profit, non-GAAP operating expenses, non-GAAP net income, and non-GAAP earnings per diluted share are exclusive of certain items to facilitate management's review of the comparability of Omnicell's core operating results on a period to period basis because such items are not related to Omnicell's ongoing core operating results as viewed by management. We define our "core operating results" as those revenues recorded in a particular period and the expenses incurred within that period that directly drive operating income in that period. Management uses these non-GAAP financial measures in making operating decisions because, in addition to meaningful supplemental information regarding operating performance, the measures give us a better understanding of how we should invest in research and development, fund infrastructure growth and evaluate the effectiveness of marketing strategies. In calculating the above non-GAAP results, management specifically adjusted for the following excluded items:

a)  Stock-based compensation expense impact of ASC 718.  We recognize equity plan-related compensation expenses, which represents the fair value of all stock-based payments to employees, including grants of employee stock options, as required under ASC 718, "Stock Compensation".

b) Restructuring charges (net of tax).  We incurred charges for employee severance in connection with a reduction in force in the first quarter of 2009, which was designed to align our cost structure with current business expectations.  These charges are not expected to be recurring and, as a non-recurring event, the financial impact is excluded from our non-GAAP results.

c) Income tax adjustments.  To provide transparency into the Company's trends and performance, we consider non-recurring research and development tax credit adjustments, to be non-GAAP adjustments.

Management adjusts for the above items because management believes that, in general, these items possess one or more of the following characteristics: their magnitude and timing is largely outside of Omnicell's control; they are unrelated to the ongoing operation of the business in the ordinary course; they are unusual and we do not expect them to occur in the ordinary course of business; or they are non-operational, or non-cash expenses involving stock option grants.

We believe that the presentation of these non-GAAP financial measures is warranted for several reasons:

1) Such non-GAAP financial measures provide an additional analytical tool for understanding Omnicell's financial performance by excluding the impact of items which may obscure trends in the core operating results of the business;

2) Since we have historically reported non-GAAP results to the investment community, we believe the inclusion of non-GAAP numbers provides consistency and enhances investors' ability to compare our performance across financial reporting periods;

3) These non-GAAP financial measures are employed by Omnicell's management in its own evaluation of performance and are utilized in financial and operational decision making processes, such as budget planning and forecasting; and

4) These non-GAAP financial measures facilitate comparisons to the operating results of other companies in our industry, which use similar financial measures to supplement their GAAP results, thus enhancing the perspective of investors who wish to utilize such comparisons in their analysis of our performance.

Set forth below are additional reasons why stock-based compensation expense related to ASC 718 is excluded from our non-GAAP financial measures:

i)  While stock-based compensation calculated in accordance with ASC 718 constitutes an ongoing and recurring expense of Omnicell, it is not an expense that requires cash settlement by Omnicell. We therefore exclude these charges for purposes of evaluating core operating results. Thus, our non-GAAP measurements are presented exclusive of stock-based compensation expense to assist management and investors in evaluating our core operating results.

ii) We present ASC 718 stock-based payment compensation expense in our reconciliation of non-GAAP financial measures on a pre-tax basis because the exact tax differences related to the timing and deductibility of stock-based compensation, under ASC 718, are dependent upon the trading price of Omnicell's common stock and the timing and exercise by employees of their stock options.  As a result of these timing and market uncertainties the tax effect related to stock-based compensation expense would be inconsistent in amount and frequency and is therefore excluded from our non-GAAP results.

As stated above, we present non-GAAP financial measures because we consider them to be important supplemental measures of performance. However, non-GAAP financial measures have limitations as an analytical tool and should not be considered in isolation or as a substitute for Omnicell's GAAP results.  In the future, we expect to incur expenses similar to certain of the non-GAAP adjustments described above and expect to continue reporting non-GAAP financial measures excluding such items. Some of the limitations in relying on non-GAAP financial measures are:

  • Omnicell's stock option and stock purchase plans are important components of incentive compensation arrangements and will be reflected as expenses in Omnicell's GAAP results for the foreseeable future under ASC 718.
  • Other companies, including other companies in Omnicell's industry, may calculate non-GAAP financial measures differently than Omnicell, limiting their usefulness as a comparative measure.

Pursuant to the requirements of SEC Regulation G, a detailed reconciliation between Omnicell's non-GAAP and GAAP financial results is set forth in the financial tables at the end of this press release. Investors are advised to carefully review and consider this information strictly as a supplement to the GAAP results that are contained in this press release and in Omnicell's SEC filings.


                             Omnicell, Inc.
            Condensed Consolidated Statements of Operations
                 (in thousands, except per share data)
                             Three Months Ended              Year Ended
                    --------------------------------  --------------------
                     December    September  December  December   December 
                     31, 2009     30, 2009  31, 2008  31, 2009   31, 2008
                    (unaudited) (unaudited)  (1)(2)  (unaudited)   (1)(2)
                    -----------  ---------- -------- ----------  ---------
      Product          $42,936    $42,854   $51,316   $170,068   $211,461
      Services and
       other revenues   11,717     11,103    10,739     43,389     40,404
                        ------     ------    ------    -------    -------
    Total revenue       54,653     53,957    62,055    213,457    251,865
                        ------     ------    ------    -------    -------
    Cost of revenues:         
      Cost of product
       revenues         20,474     20,087    24,202     80,016     97,461
      Cost of services
       and other
       revenues          6,956      6,621     6,687     27,011     25,770
       charges               -          -         -      1,209          -
                        ------     ------    ------    -------    -------
    Total cost of
     revenues           27,430     26,708    30,889    108,236    123,231
                        ------     ------    ------    -------    -------
    Gross profit        27,223     27,249    31,166    105,221    128,634
    Operating expenses:
      Research and
       development       4,037      4,981     4,256     17,569     18,196
      Selling, general,
       administrative   21,807     21,324    23,152     85,668     93,098
       charges               -          -         -      1,315          -
                        ------     ------    ------    -------    -------
    Total operating
     expenses           25,844     26,305    27,408    104,552    111,294
                        ------     ------    ------    -------    -------
    Income from
     operations          1,379        944     3,758        669     17,340
    Other income and
     expense, net           91         56       578        523      3,382
                        ------     ------    ------    -------    -------
    Income before
     for income taxes    1,470      1,000     4,336      1,192     20,722
    Provision for
     income taxes          913        146     1,013        748      7,998
                        ------     ------    ------    -------    -------
    Net income            $557       $854    $3,323       $444    $12,724
                        ======     ======    ======    =======    =======
    Net income per
      Basic              $0.02      $0.03     $0.11      $0.01      $0.40
      Diluted            $0.02      $0.03     $0.10      $0.01      $0.38
    Weighted average
      Basic             31,927     31,704    31,265     31,691     32,076
      Diluted           32,513     32,380    31,849     32,063     33,108
    (1) Information derived from our December 31, 2008 audited Consolidated
        Financial Statements.
    (2) Certain amounts which are not material have been reclassified to
        conform with our current presentation in both product revenue and
        service revenue.
                                Omnicell, Inc.
                     Condensed Consolidated Balance Sheets
                               (In thousands)
                                                    December 31,  December 31,
                                                       2009          2008
                                                    ------------  ------------
                                                      (unaudited)     (1)
    Current assets:
      Cash and cash equivalents                       $169,230    $120,439
      Accounts receivable, net                          42,511      57,976
      Inventories                                        9,582      12,957
      Prepaid expenses                                   8,779       9,310
      Deferred tax assets                               15,247      14,871
      Other current assets                               5,870       9,434
                                                      --------    --------
        Total current assets                           251,219     224,987
    Property and equipment, net                         13,209      16,180
    Non-current net investment in
     sales-type leases                                   8,709      10,896
    Goodwill                                            24,982      24,982
    Other intangible assets                              4,232       6,706
    Non-current deferred tax assets                      9,666      15,889
    Other assets                                         9,322       8,902
                                                      --------    --------
          Total assets                                $321,339    $308,542
                                                      ========    ========
    Current liabilities:
      Accounts payable                                 $10,313      $9,377
      Accrued compensation                               8,095       8,889
      Accrued liabilities                               11,997      10,357
      Deferred service revenue                          14,457      12,084
      Deferred gross profit                             12,768      16,648
                                                      --------    --------
        Total current liabilities                       57,630      57,355
    Long-term deferred service revenue                  20,810      16,782
    Other long-term liabilities                            595         848
                                                      --------    --------
        Total liabilities                               79,035      74,985
    Stockholders' equity:
        Total stockholders' equity                     242,304     233,557
                                                      --------    --------
          Total liabilities and
           stockholders' equity                       $321,339    $308,542
                                                      ========    ========
    (1) Information derived from our December 31, 2008 audited Consolidated
        Financial Statements.
                              Omnicell, Inc.
                    Reconciliation of GAAP to Non-GAAP
              (In thousands, except per share data, unaudited)
                                   Three months ended
                      December 31,        September 30,     December 31,
                          2009                2009             2008
                     -----------------  ----------------- -----------------
                              Earnings          Earnings           Earnings
                                per               per                per
                      Net     share-     Net    share-     Net     share-
                     income   diluted   income  diluted   income   diluted 
                     ------   --------  ------  --------  ------   --------
    GAAP              $557     $0.02      $854    $0.03   $3,323     $0.10
    ASC 718
     adjustment (a)       
       Margin          453                 360               283
       Expenses      2,001               2,053             2,113
     adjustment (c)    422                                  (246)
                    ------              ------            ------
                     2,876      0.09     2,413     0.07    2,150      0.07
    Non-GAAP        $3,433     $0.11    $3,267    $0.10   $5,473     $0.17
                    ======     =====    ======    =====   ======     =====
                                            Year ended
                           December 31, 2009         December 31, 2008
                       ----------------------     ------------------------
                                  Earnings                       Earnings
                        Net       per share -       Net         per share-
                       income      diluted        income         diluted
                       ------     -----------     ------        ----------
    GAAP                $444         $0.01       $12,724          $0.38
    ASC 718
     adjustment (a)
      Gross Margin     1,478                       1,610
       Expenses        8,247                       9,555
     cost (net of
     tax) (b)
      Gross profit       735
       expenses          799
     tax adjustment
     (c)                 422                        (246)
                     -------         -----       -------          -----
                      11,681          0.37        10,919           0.33
    Non-GAAP         $12,125         $0.38       $23,643          $0.71
                     =======         =====       =======          =====
    (a) This adjustment reflects the accounting impact of non-cash stock-based
        compensation expense related to the impact of ASC 718 (formerly
        referred to as SFAS No. 123R) for the periods shown.
    (b) This is the net of tax impact of the restructuring activities
        commenced during the first quarter of 2009.
    (c) This adjustment reflects the impact on the Company's income tax
        provision (benefit) from non-recurring liability adjustments primarily
        related to research and development tax credits.

SOURCE Omnicell, Inc.



SOURCE Omnicell, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

2. Omnicell Selected by Nations Third Largest Public Healthcare System for Medication Management Systems
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, ... ... School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, ... professionals on guideline updates for the primary prevention of cardiovascular diseases during ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... will be giving viewers the lowdown on sciatica in a new episode of ... that focuses on current events and innovation and investigates each subject in-depth with ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
Breaking Medicine News(10 mins):